Abstract:Objective To study the value of serum fibroblast growth factor 23 (FGF23) in the diagnosis of hypophosphatemic rickets in children. Methods A total of 28 children who were diagnosed with hypophosphatemic rickets in Children's Hospital of Nanjing Medical University from January 2016 to June 2021 were included as the rickets group. Forty healthy children, matched for sex and age, who attended the Department of Child Healthcare of the hospital were included as the healthy control group. The serum level of FGF23 was compared between the two groups, and the correlations of the serum FGF23 level with clinical characteristics and laboratory test results were analyzed. The value of serum FGF23 in the diagnosis of hypophosphatemic rickets was assessed. Results The rickets group had a significantly higher serum level of FGF23 than the healthy control group (P<0.05). In the rickets group, the serum FGF23 level was positively correlated with the serum alkaline phosphatase level (rs=0.38, P<0.05) and was negatively correlated with maximum renal tubular phosphorus uptake/glomerular filtration rate (rs=-0.64, P<0.05), while it was not correlated with age, height Z-score, sex, and parathyroid hormone (P>0.05). Serum FGF23 had a sensitivity of 0.821, a specificity of 0.925, an optimal cut-off value of 55.77 pg/mL, and an area under the curve of 0.874 in the diagnosis of hypophosphatemic rickets (P<0.05). Conclusions Serum FGF23 is of valuable in the diagnosis of hypophosphatemic rickets in children, which providing a theoretical basis for early diagnosis of this disease in clinical practice.
DONG Sha-Sha,CHE Ruo-Chen,ZHENG Bi-Xia et al. Value of serum fibroblast growth factor 23 in diagnosis of hypophosphatemic rickets in children[J]. CJCP, 2023, 25(7): 705-710.
Trombetti A, Al-Daghri N, Brandi ML, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia[J]. Nat Rev Endocrinol, 2022, 18(6): 366-384. PMID: 35484227. DOI: 10.1038/s41574-022-00662-x.
Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23[J]. Mol Cell Endocrinol, 2011, 347(1-2): 17-24. PMID: 21914460. DOI: 10.1016/j.mce.2011.08.030.
Kinoshita Y, Fukumoto S. X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment[J]. Endocr Rev, 2018, 39(3): 274-291. PMID: 29381780. DOI: 10.1210/er.2017-00220.
Smith ER, McMahon LP, Holt SG. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs[J]. Clin Chem Lab Med, 2013, 51(10): 1971-1981. PMID: 23729624. DOI: 10.1515/cclm-2013-0208.
Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets[J]. Eur J Pediatr, 1998, 157(11): 894-900. PMID: 9835432. DOI: 10.1007/s004310050962.
Whyte MP, Carpenter TO, Gottesman GS, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial[J]. Lancet Diabetes Endocrinol, 2019, 7(3): 189-199. PMID: 30638856. DOI: 10.1016/S2213-8587(18)30338-3.
Brandi ML, Jan de Beur S, Briot K, et al. Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post Hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study[J]. Calcif Tissue Int, 2022, 111(4): 409-418. PMID: 35927518. DOI: 10.1007/s00223-022-01006-7.
Sharma S, Katz R, Bullen AL, et al. Intact and C-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes?[J]. J Clin Endocrinol Metab, 2020, 105(12): e4875-e4885. PMID: 32951052. PMCID: PMC7571450. DOI: 10.1210/clinem/dgaa665.
Smith ER, Cai MM, McMahon LP, et al. Biological variability of plasma intact and C-terminal FGF23 measurements[J]. J Clin Endocrinol Metab, 2012, 97(9): 3357-3365. PMID: 22689697. DOI: 10.1210/jc.2012-1811.
Hamano T. Mineral and bone disorders in conventional hemodialysis: challenges and solutions[J]. Semin Dial, 2018, 31(6): 592-598. PMID: 29900589. DOI: 10.1111/sdi.12729.
Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia[J]. J Clin Endocrinol Metab, 2006, 91(6): 2055-2061. PMID: 16551733. DOI: 10.1210/jc.2005-2105.
Ito N, Kubota T, Kitanaka S, et al. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23[J]. J Bone Miner Metab, 2021, 39(6): 1066-1075. PMID: 34255195. DOI: 10.1007/s00774-021-01250-1.
Yamamoto T, Imanishi Y, Kinoshita E, et al. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome[J]. J Bone Miner Metab, 2005, 23(3): 231-237. PMID: 15838626. DOI: 10.1007/s00774-004-0589-9.
Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism[J]. J Clin Invest, 2004, 113(4): 561-568. PMID: 14966565. PMCID: PMC338262. DOI: 10.1172/JCI19081.